U.S. Markets closed
  • S&P Futures

    4,383.50
    +3.75 (+0.09%)
     
  • Dow Futures

    34,781.00
    +60.00 (+0.17%)
     
  • Nasdaq Futures

    14,954.25
    +1.50 (+0.01%)
     
  • Russell 2000 Futures

    2,213.00
    +2.10 (+0.09%)
     
  • Crude Oil

    71.43
    +0.17 (+0.24%)
     
  • Gold

    1,815.40
    -6.80 (-0.37%)
     
  • Silver

    25.41
    -0.17 (-0.66%)
     
  • EUR/USD

    1.1878
    +0.0001 (+0.0119%)
     
  • 10-Yr Bond

    1.1740
    -0.0650 (-5.25%)
     
  • Vix

    19.46
    +1.22 (+6.69%)
     
  • GBP/USD

    1.3893
    +0.0009 (+0.0667%)
     
  • USD/JPY

    109.2320
    -0.0770 (-0.0704%)
     
  • BTC-USD

    39,021.30
    -622.70 (-1.57%)
     
  • CMC Crypto 200

    951.42
    -9.47 (-0.99%)
     
  • FTSE 100

    7,081.72
    +49.42 (+0.70%)
     
  • Nikkei 225

    27,499.41
    -281.61 (-1.01%)
     

Global Hereditary Angioedema Clinical Trial Pipeline Research Report-2025: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage 2021 - ResearchAndMarkets.com

·2 min read

DUBLIN, July 21, 2021--(BUSINESS WIRE)--The "Global Hereditary Angioedema Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Hereditary Angioedema Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Hereditary Angioedema market. It covers emerging therapies for Hereditary Angioedema in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Hereditary Angioedema pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Hereditary Angioedema pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Hereditary Angioedema pipeline products by the company.

Short-term Launch Highlights:

Find out which Hereditary Angioedema pipeline products will be launched in the US and Ex-US till 2025.

SUMMARY:

  • Hereditary Angioedema phase 3 clinical trial pipeline products

  • Hereditary Angioedema phase 2 clinical trial pipeline products

  • Hereditary Angioedema phase 1 clinical trial pipeline products

  • Hereditary Angioedema preclinical research pipeline products

  • Hereditary Angioedema discovery stage pipeline products

  • Hereditary Angioedema pipeline products short-term launch highlights

Countries Covered

  • Global

  • Europe

  • US

  • Germany

  • France

  • UK

  • Spain

  • Italy

  • Japan

For more information about this report visit https://www.researchandmarkets.com/r/foscvy

View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005658/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900